K. Sandberg et al., Preterm infants with low immunoglobulin G levels have increased risk of neonatal sepsis but do not benefit from prophylactic immunoglobulin G, J PEDIAT, 137(5), 2000, pp. 623-628
Objective: In a prospective, randomized, placebo-controlled, multicenter st
udy, we evaluated the prevention of neonatal infections with intravenous im
munoglobulin G (IVIgG) prophylaxis For preterm infants (gestational age <33
weeks) with umbilical cord blood IgG levels <less than or equal to>4 g/L.
Study design: Intravenous Ige or placebo (albumin), 1 g/kg body weight, was
given on days 0, 3, 7, 14, and 21 to 81 infants with umbilical cord blood
IgG levels 14 g/L: (1) IVIgG group, n = 40, mean (SD) gestational age 27.5
(2.2) weeks and birth weight 1.06 (0.39) kg; (2) placebo group, n = 41, mea
n (SD) gestational age 27.7 (2.5) weeks and birth weight 1.13 (0.38) kg. In
fants with umbilical cord blood IgG levels 24 g/L (n = 238) served as a sep
arate comparison group. Neonatal infections according to European Society o
f Pediatric Infectious Disease criteria were monitored until 28 days of lif
e.
Results: Infants with IgG levels less than or equal to4 g/L at birth who re
ceived IVIgG had no significant reduction in infectious episodes or mortali
ty rate when compared with those given placebo. However, infants with a ser
um concentration of IgG >4 g/L at birth had significantly fewer infectious
episodes (culture-proven sepsis) than infants with low serum concentrations
of IgG (14 g/L) when compared at the same gestational ages (26 to 29 weeks
, P < .003).
Conclusions: Prophylactic immunotherapy with IVIgG did not improve the immu
ne competence in preterm infants with low serum IgG concentrations at birth
. We speculate that a spontaneously high serum IgG concentration at birth r
eflects placenta function and is an indicator of a more mature immune syste
m capable of protecting the preterm infant against severe neonatal infectio
ns.